Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Medicine type
Approval status
AllApproved in the United States (FDA)Approved in the European Union (EMA)In Phase 3 testingIn Phase 2 testingUsed in a way not covered by an approval, or made by a compounding pharmacyDietary supplement; not FDA-approved as a medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Laboratory or animal-stage researchControlled substance; no approved US useWithdrawn from the market
Amount of information
Showing 1–7 of 7 records
Inotersen (Tegsedi)
Gene-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Hereditary ATTR Amyloidosis with Nerve Damage
Nusinersen (Spinraza)
Gene-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Spinal Muscular Atrophy
Eplontersen (Wainua)
Gene-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Hereditary ATTR Amyloidosis with Nerve Damage
Mipomersen (Kynamro)
Gene-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Homozygous Familial Hypercholesterolaemia (withdrawn)
Fomivirsen (Vitravene Preservative Free)
Gene-silencing medicineApproved in the United States (FDA)Expanded recordOlezarsen (Tryngolza (Autoinjector) / Tryngolza)
Gene-silencing medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Triglycerides
Donidalorsen (Dawnzera (Autoinjector) / Dawnzera)
Gene-silencing medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Prophylaxis to prevent attacks of hereditary angioedema